Sign in
Not yet taking people in United StatesPhase 1

Tests 177Lu-DTPA-SC16.56 in people with neuroendocrine lung and prostate cancers

Tests whether 177Lu-DTPA-SC16.56 is safe in adults with neuroendocrine lung or prostate cancer.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 7 sites
Trial code
Registry title
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Status
Not yet recruiting
Phase
Phase 1
People taking part
12 people, planned
Starts
Dec 2026
Expected to end
May 2030
Type of study
Interventional, 2 groups
Treatments tested
  • PET/CT
  • 177Lu-DTPA-SC16.56
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced small-cell lung cancer or neuroendocrine prostate cancer that has come back or grown after at least 1 line of standard chemotherapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Proven, growing, spread (metastatic) high-grade neuroendocrine cancer of the lung (small-cell lung cancer) or prostate (neuroendocrine prostate cancer). At least one tumor of 2 cm (0.8 in) or more on CT or MR.
Earlier treatment
At least 1 line of standard chemotherapy, with the disease coming back afterwards. Earlier chemotherapy, immunotherapy or investigational drugs must have ended at least 4 weeks before joining. Earlier treatment with Rova-T (rovalpituzumab) is not allowed.
Biomarker or test result
The tumors must show a high level of DLL3 on the scan (SUVmax greater than in normal liver) in at least 80% of growing tumors of 2 cm (0.8 in) or more. Prostate cancer must show neuroendocrine features, for example chromogranin staining, small cell look, or DLL3 positivity.

Main reasons for not taking part

  • Past severe allergic reaction to human or humanized antibodies, or to X-ray contrast medium despite premedication
  • Pregnant, or unwilling to stop breastfeeding
  • Life expectancy under 6 months
  • Brain metastases or spinal cord compression that are not treated and stable
  • Other ongoing invasive cancer, or a treated cancer with more than 30% chance of coming back within two years

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Subjects with histologically proven progressive metastatic high-grade neuroendocrine carcinomas of the lung (small-cell lung cancer) and prostate (neuroendocrine prostate cancer) that has relapsed following at least 1 line of standard chemotherapy i. Prostate cancer patients will be defined by either of the following criteria: ii. The presence of chromogranin staining on tissue iii. At least two of the pathogenic mutations of PTEN, RB1, or p53 iv. Disease exclusively involving the viscera v. Disease in which the PSA is <10 but the number of bone lesions is >20 vi. Histologic evidence of small cell carcinoma or other stains consistent with neuroendocrine disease (on the primary disease or metastases) vii. DLL3 positivity on previously available tissue specimens
  • Ability to understand and willingness to sign a written informed consent document
  • Aged 18 years or older at the time of signing consent
  • Progression of disease defined by one of the following occurring within 3 months of study entry:; At least a 20% increase in radiologically or clinically measurable disease; ii. Appearance of any new lesion; iii. For prostate cancer patients progression criteria will be per PCWG3: iv. Either v. A rising PSA over a sequence of at least 1-week intervals OR i. An increase in soft tissue disease to qualify for disease progression by RECIST 1.1 OR ii. Two new bone lesions by bone scintigraphy; Patients with metastatic disease by virtue of disease exclusively evident by PSMA PET will not be eligible. All patients must have metastatic disease by evidence of standard scintigraphic or anatomic imaging in accord with PCWG3
  • At least one tumor lesion on CT or MR ≥ 2 cm
  • ECOG performance status 0 to 2
  • Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
  • Previous chemotherapy, immunotherapy, and/or investigational agents are allowed if completed ≥4 weeks prior to study entry. For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry
  • Preserved hematological function:; Hb ≥9.0 g/dL; ii. WBC ≥3000/mm3; iii. ANC≥1500/mm3; iv. Platelets ≥75.000/mm3
  • Preserved renal function:; Serum creatinine ≤1.7 mg/dL ii. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73m2
  • Preserved hepatic function:; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x upper limit of normal (ULN) or ≤ 5 x ULN if liver metastases are present ii. bilirubin ≤ 1.5 x ULN (unless considered due to Gilbert's syndrome or hemolysis)
  • Willingness to undergo baseline and follow up biopsy to obtain tissue for DLL3 IHC and genomic analyses
  • In order to proceed with the treatment with 177Lu-DTPA-SC16.56, patients must exhibit overexpression of DLL3, as SUVmax greater than in normal liver, in ≥80% of tumor lesions among the growing progressing lesions that are ≥2cm

Who cannot take part

  • Prior treatment with Rova-T (rovalpituzumab)
  • Spinal cord compression or symptomatic/uncontrolled epidural disease, unless treated and stable for at least 1 week prior to enrolment
  • Males and females of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 4 months for males and 7 months for females after receiving the therapeutic study drug. Acceptable methods of highly effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with hormonal birth control or intrauterine device (IUD) (women)
  • Unresolved toxicities from prior antitumor therapy, defined per Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, to to grade 1 or grade 0 or to levels dictated in the inclusion criteria
  • Major surgery within 28 days of enrolment with the exception of biopsy and insertion of central venous catheter
  • Concurrent chemotherapy, other radiopharmaceuticals of any type, and immunotherapy are excluded
  • History of anaphylactic reaction to humanized or human antibodies
  • History of severe allergic reaction to X-ray contrast medium despite premedication
  • Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Other ongoing invasive malignances (i.e., not carcinomas in situ, non-mm invasive urothelial cancer, or other non-invasive tumors), and prior cancers that have been treated that have a >30% likelihood of relapse within the next two years
  • Prostate cancer patients with mixed histologies (i.e., neuroendocrine and adenocarcinomas) are eligible provided that they meet all of the above eligibility criteria
  • Patients for whom their clinicians believe would benefit by continuing their treatments for their disease to control any adenocarcinoma (such as ADT or other AR axis directed therapy) can and should remain on those treatments while on this protocol, if their clinician believes that it would be clinically beneficial to do so
  • Women who are pregnant or unwilling to discontinue breastfeeding
  • Life expectancy < 6 months as assessed by the treating physician
  • Known parenchymal brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized
  • Unmanageable urinary incontinence rendering the administration of 177Lu-DTPA-SC16.56 unsafe (e.g., urinary catheterization not feasible)
  • Subjects likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge
  • Complementary approaches known to modulate PSA should not be taken while on this trial

Where in United States

  • Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesContact: Lisa Bodei, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer

The 2 groups in the trial

  • Participants with neuroendocrine carcinomas of the lungTreatment being tested

    Treatment: PET/CT and 177Lu-DTPA-SC16.56

  • Participants with neuroendocrine prostate cancerTreatment being tested

    Treatment: PET/CT and 177Lu-DTPA-SC16.56

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate
Plain-language title
Tests 177Lu-DTPA-SC16.56 in people with neuroendocrine lung and prostate cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate (NCT06941480) – Frontlight Research